Amivantamab drug page Clinical trials

Trials with Amivantamab

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

7Trials
6Recruiting
23Countries
3.727Planned patients

Showing 1–7 of 7

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Recruiting Phase 3 700 patients NCT06750094

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…

United States, Australia, Belgium, Brazil and 7 more Dec 2024 – Apr 2029 Interventional
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Recruiting Phase 3 1.000 patients NCT06662786

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…

United States, Belgium, Brazil, Canada and 8 more Oct 2024 – Jan 2032 Interventional
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Recruiting Phase 2 197 patients NCT05845450

This is a window-of-opportunity umbrella platform trial enrolling non-metastatic resectable colorectal patients selected for the presence of a specific targetable molecular alteration. The study aims to test the activity of specific target…

Italy May 2023 – May 2028 Interventional
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Recruiting Phase 2 520 patients NCT05498428

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combinat…

United States, Brazil, China, France and 8 more Nov 2022 – Aug 2028 Interventional
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Recruiting Phase 1 225 patients NCT05379595

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) a…

United States, Belgium, Canada, China and 7 more Jul 2022 – Oct 2030 Interventional
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Recruiting Phase 2 1.000 patients NCT03767075

The global objective of this Basket of Basket study is to evaluate the antitumor activity of each matched therapies that will be evaluated through the study in small molecularly selected populations. The objective of module 1 wil be to de…

France, Germany, Italy, Netherlands and 3 more Dec 2018 – Nov 2026 Interventional
Combined with: AtezolizumabFutibatinib
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatm
Not yet recruiting Phase 2 85 patients NCT06855849

This trial is a multicenter, single arm study of efficacy of amivantamab in combination with FOLFIRI in RAS/BRAF wild-type advanced colorectal cancer patients progressed prior treatment including oxaliplatin based chemotherapy. This trial …

South Korea May 2025 – Dec 2027 Interventional

Where the recruiting trials are